BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reszke R, Krajewski P, Szepietowski JC. Emerging Therapeutic Options for Chronic Pruritus. Am J Clin Dermatol 2020;21:601-18. [PMID: 32607945 DOI: 10.1007/s40257-020-00534-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ruppenstein A, Limberg MM, Loser K, Kremer AE, Homey B, Raap U. Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions. Front Med (Lausanne) 2021;8:627985. [PMID: 33681256 DOI: 10.3389/fmed.2021.627985] [Reference Citation Analysis]
2 French AR, van Rijn RM. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kim HS, Hashimoto T, Fischer K, Bernigaud C, Chosidow O, Yosipovitch G. Scabies itch: an update on neuroimmune interactions and novel targets. J Eur Acad Dermatol Venereol 2021;35:1765-76. [PMID: 33960033 DOI: 10.1111/jdv.17334] [Reference Citation Analysis]
4 Knapp C 3rd, Steele E, Mengden-Koon S, Williams T, Fett N. A Case of Tofacitinib-Induced Lymphomatoid Papulosis With Ocular Involvement. Am J Dermatopathol 2022. [PMID: 35503884 DOI: 10.1097/DAD.0000000000002219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kabashima K, Irie H. Interleukin-31 as a Clinical Target for Pruritus Treatment. Front Med (Lausanne) 2021;8:638325. [PMID: 33644103 DOI: 10.3389/fmed.2021.638325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]